NCT04985825 (I-PACE) is a Phase 2 clinical trial of Imgatuzumab in Cutaneous Squamous Cell Carcinoma, sponsored by Pega-One S.A.S..

Who is sponsoring NCT04985825?

NCT04985825 is sponsored by Pega-One S.A.S..

What drugs are being tested in NCT04985825?

Interventions in NCT04985825: Imgatuzumab.

What condition does NCT04985825 study?

NCT04985825 studies Cutaneous Squamous Cell Carcinoma.

Is NCT04985825 still recruiting?

NCT04985825 is currently withdrawn. Last updated 13 September 2022.

Last reviewed 2022-09-13 · How we verify

NCT04985825: I-PACE

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Imgatuzumab in Patients With Advanced Cutaneous Squamous Cell Carcinoma

Withdrawn Phase 2 Last updated 13 September 2022

What this trial tests

Phase 2 trial testing Imgatuzumab in Cutaneous Squamous Cell Carcinoma. Withdrawn.

Timeline

16 December 2021

Primary endpoint
17 August 2022

17 August 2022

Quick facts

Lead sponsor	Pega-One S.A.S.
Phase	Phase 2
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Start date	16 December 2021
Primary completion	17 August 2022
Estimated completion	17 August 2022

Drugs / interventions tested

Imgatuzumab — full drug profile →

Conditions studied

Cutaneous Squamous Cell Carcinoma — all drugs for Cutaneous Squamous Cell Carcinoma →

Sponsor

Pega-One S.A.S.

Who can join

18 and older, any sex, with Cutaneous Squamous Cell Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will evaluate the anti-tumor activity, safety, tolerability, immunogenicity, pharmacokinetics, and pharmacodynamics of imgatuzumab, a monoclonal antibody against epidermal growth factor receptor (EGFR) with enhanced antibody-dependent cellular cytotoxicity (ADCC) in patients with advanced cutaneous squamous cell carcinoma (CSCC). Quality of life of patients treated with imgatuzumab will also be assessed.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Cutaneous Squamous Cell Carcinoma

Currently open trials in the same condition.

NCT07288073 — TIL Therapy in cSCC and MCC · Phase 2 · recruiting
NCT07402616 — Ex Vivo Cutaneous SCC · NA · recruiting
NCT06875609 — ctDNA in Cutaneous Squamous Cell Carcinoma · recruiting
NCT06567314 — Phase 2 Study of Ivonescimab in Patients With Cutaneous Squamous Cell Carcinoma · Phase 2 · recruiting
NCT06659146 — Thermotherapy in Addition to SOC Palliative Radiotherapy · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04985825 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Pega-One S.A.S.
Last refreshed: 13 September 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04985825.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing